Gapping down
In reaction to disappointing earnings/guidance:
- SSI -25%, TDOC -10.5%, RMGN -10.2%, MEI -9.8%, JUNO -7.1%, PSTG -6.9%, PLNT -6.2%, PDLI -5.7%
- NKTR -4.8%, OPK -4.4%, KR -4.2%, SHAK -3.8%, BUD -3.8%, RTRX -3.5%, ABEV -3.5%, VGR -2.9%, ATHM -2.1%
- CIO -2%, PRTK -1.7%, FSIC -1.4%, GCP -1.3%, PFMT -1.1%, BOX -1%
Select metals/mining stocks trading lower:
- HMY -3.5%, MTL -3%, AU -1.8%, GFI -1.6%, ABX -1.6%
- GDX -1.5%, NEM -1.5%, SLW -1.3%, GOLD -1%, AG -0.9%
Other news:
- ADPT -29% (files to delay Form 10-K )
- PBYI -20.8% (after Roche's (RHHBY) Phase III APHINITY study for Perjeta met its primary endpoint treating breast cancer; also reported earnings)
- PTCT -18.5% (Ataluren Confirmatory Trial in nonsense mutation cystic fibrosis did not achieve its primary or secondary endpoints)
- AXTI -11.3% (prices its previously announced underwritten public offering of 4,615,385 shares of its common stock at a price to the public of $6.50/share)
- ARES -9.1% (commences a public offering of 7.5 mln common units representing limited partnership interests by a selling unitholder)
- AHP -5.8% (commences offerings of 1,150,000 shares of 5.50% Series B Cumulative Convertible Preferred Stock and 5.75 mln of its common stock)
- KITE -3.4% (commences 4.75 mln common stock offering; also downgraded to Neutral from Buy at Citigroup)
Analyst comments:
- AEO -0.5% (downgraded to Neutral at BofA/Merrill)